Zepbound Outperforms CagriSema in Head to Head Phase III Obesity Trial Tirzepatide, a dual GIP GLP 1 receptor co agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction Cardiovascular Diabetology Springer Nature Link When semaglutide and tirzepatide stop working for patients, Im adding in cagrilintide. Cagrilintide can add as much as 9% more weight loss to already used GLP1s such as semaglutide, tirzepatide or Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed